Fulcrum Therapeutics to participate in the 44th Annual J.P. Morgan Healthcare Conference. CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) - Fulcrum Therapeutics, Inc.(R)(Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics' website for at least 30 days following the presentation. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has priced its public offering of 11.85 million common shares at $13.50 each and pre-funded warrants for 1.11 million additional shares at $13.499 per warrant. The offering is expected to raise approximately $175 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to 1.94 million additional shares. Proceeds will support general corporate purposes, including research and development for clinical programmes, particularly pociredir, its lead treatment for sickle cell disease. J.P. Morgan, Leerink Partners and Cantor are serving as book-running managers, with Oppenheimer & Co. and Truist Securities also participating. The offering is expected to close on 11 December 2025, subject to customary conditions.